1
|
Pezoulas V, Nowakowska K, Kazmierski J, Fotiadis D, Sakellarios A. Prediction of depression among patients with cardiovascular disease scheduled cardiac surgery using an AI-empowered pipeline. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.2428] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Introduction
Several studies have demonstrated, that one in three patients with cardiovascular disease (CVD) suffers from depression, and depression increases the likelihood for cardiac morbidity and mortality in the CVD population by 2–3-fold, independently of traditional risk factors or gender.
Purpose
The aim of this work is to predict depression in patients with CVD.
Methods
The clinical study was conducted in the cardiac surgical intensive care unit of The Central Clinical Hospital, the Medical University of Lodz in Poland, among patients scheduled for elective coronary artery bypass graft surgery (CABG). 224 patients signed an informed consent form, met the inclusion criteria and were enrolled in the study. All the patients had chronic coronary syndromes. The inclusion criteria were: consecutive adult patients scheduled for CABG surgery or CABG surgery with cardiac valve repair or replacement (CVR). The study population was examined by a psychiatrist the day prior to the scheduled operation, a diagnosis of major depressive disorder (MDD) was established on the basis of DSM-5 criteria.
A data curation pipeline was applied to automatically remove outliers and duplicated fields in the input dataset. An AI-empowered pipeline was developed to classify patients at higher risk for depression. Random downsampling with replacement was applied to deal with the increased class imbalance by taking into consideration two confound factors, namely the Mini Mental State Examination and Hemoglobin concentration <10mg/dl. The downsampling process was repeated K times. In each iteration, three bagging and boosting ML schemas were utilized for the classification task including the AdaBoost (adaptive boosting), Random Forests and Extreme Gradient boosting trees (XGBoost). To this end, a nested cross-validation process was applied for hyperparameter optimization and model validation, where: (i) a 3-fold cross-validation process was first applied to seek for the optimal set of hyperparameters based on the grid search approach by tuning core parameters, including the learning rate, number of estimators, and max depth, among others, and (ii) a stratified 5-fold cross-validation process was subsequently used to evaluate the performance of the best model from the previous stage by computing the classification accuracy, sensitivity, specificity, and area under the ROC curve (AUC). The performance evaluation results were averaged across the 5 folds and across the downsampling iterations. Shappley additive explanation analysis was finally applied to provide explainable risk factors for depression.
Results
sRAGE was significantly correlated with depression (r=0.32, p=0.038). The Random forests classifier presented the highest performance to predict depression (Accuracy: 0.71, Sensitivity: 0.71, Specificity: 0.75 and AUC: 0.74).
Conclusions
Depression can be predicted with 71% accuracy at patients with CVD and elevated sRAGE values.
Funding Acknowledgement
Type of funding sources: Public grant(s) – EU funding. Main funding source(s): HORIZON2020
Collapse
Affiliation(s)
- V Pezoulas
- University of Ioannina , Ioannina , Greece
| | | | | | - D Fotiadis
- Foundation for Research and Technology - Hellas , Ioannina , Greece
| | - A Sakellarios
- Foundation for Research and Technology - Hellas , Ioannina , Greece
| |
Collapse
|
2
|
Grist E, Friedrich S, Brawley C, Mendes L, Parry M, Ali A, Haran A, Hoyle A, Gilson C, Lall S, Zakka L, Bautista C, Landless A, Nowakowska K, Wingate A, Wetterskog D, Hasan AMM, Akato NB, Richmond M, Ishaq S, Matthews N, Hamid AA, Sweeney CJ, Sydes MR, Berney DM, Lise S, Parmar MKB, Clarke NW, James ND, Cremaschi P, Brown LC, Attard G. Accumulation of copy number alterations and clinical progression across advanced prostate cancer. Genome Med 2022; 14:102. [PMID: 36059000 PMCID: PMC9442998 DOI: 10.1186/s13073-022-01080-4] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/13/2022] [Accepted: 06/23/2022] [Indexed: 01/19/2023] Open
Abstract
BACKGROUND Genomic copy number alterations commonly occur in prostate cancer and are one measure of genomic instability. The clinical implication of copy number change in advanced prostate cancer, which defines a wide spectrum of disease from high-risk localised to metastatic, is unknown. METHODS We performed copy number profiling on 688 tumour regions from 300 patients, who presented with advanced prostate cancer prior to the start of long-term androgen deprivation therapy (ADT), in the control arm of the prospective randomised STAMPEDE trial. Patients were categorised into metastatic states as follows; high-risk non-metastatic with or without local lymph node involvement, or metastatic low/high volume. We followed up patients for a median of 7 years. Univariable and multivariable Cox survival models were fitted to estimate the association between the burden of copy number alteration as a continuous variable and the hazard of death or disease progression. RESULTS The burden of copy number alterations positively associated with radiologically evident distant metastases at diagnosis (P=0.00006) and showed a non-linear relationship with clinical outcome on univariable and multivariable analysis, characterised by a sharp increase in the relative risk of progression (P=0.003) and death (P=0.045) for each unit increase, stabilising into more modest increases with higher copy number burdens. This association between copy number burden and outcome was similar in each metastatic state. Copy number loss occurred significantly more frequently than gain at the lowest copy number burden quartile (q=4.1 × 10-6). Loss of segments in chromosome 5q21-22 and gains at 8q21-24, respectively including CHD1 and cMYC occurred more frequently in cases with higher copy number alteration (for either region: Kolmogorov-Smirnov distance, 0.5; adjusted P<0.0001). Copy number alterations showed variability across tumour regions in the same prostate. This variance associated with increased risk of distant metastases (Kruskal-Wallis test P=0.037). CONCLUSIONS Copy number alteration in advanced prostate cancer associates with increased risk of metastases at diagnosis. Accumulation of a limited number of copy number alterations associates with most of the increased risk of disease progression and death. The increased likelihood of involvement of specific segments in high copy number alteration burden cancers may suggest an order underlying the accumulation of copy number changes. TRIAL REGISTRATION ClinicalTrials.gov NCT00268476 , registered on December 22, 2005. EudraCT 2004-000193-31 , registered on October 4, 2004.
Collapse
Affiliation(s)
- Emily Grist
- Cancer Institute, University College London, London, UK
| | | | | | | | - Marina Parry
- Cancer Institute, University College London, London, UK
| | - Adnan Ali
- GU Cancer Research/FASTMAN Group, Manchester Cancer Institute, Manchester, UK
| | - Aine Haran
- The Christie and Salford Royal NHS Foundation Trusts, Manchester, UK
| | - Alex Hoyle
- The Christie and Salford Royal NHS Foundation Trusts, Manchester, UK
| | - Claire Gilson
- MRC Clinical Trials Unit at University College London, London, UK
| | | | - Leila Zakka
- Cancer Institute, University College London, London, UK
| | | | - Alex Landless
- Cancer Institute, University College London, London, UK
| | | | - Anna Wingate
- Cancer Institute, University College London, London, UK
| | | | | | - Nafisah B Akato
- MRC Clinical Trials Unit at University College London, London, UK
| | - Malissa Richmond
- MRC Clinical Trials Unit at University College London, London, UK
| | - Sofeya Ishaq
- MRC Clinical Trials Unit at University College London, London, UK
| | - Nik Matthews
- The Institute of Cancer Research, London, UK
- Imperial College, London, UK
| | - Anis A Hamid
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA
| | | | - Matthew R Sydes
- MRC Clinical Trials Unit at University College London, London, UK
| | - Daniel M Berney
- Barts Cancer Institute, Queen Mary University of London, London, UK
| | - Stefano Lise
- Cancer Institute, University College London, London, UK
| | | | - Noel W Clarke
- GU Cancer Research/FASTMAN Group, Manchester Cancer Institute, Manchester, UK
| | - Nicholas D James
- The Royal Marsden Hospital NHS Foundation Trust and The Institute of Cancer Research, London, UK
| | | | - Louise C Brown
- MRC Clinical Trials Unit at University College London, London, UK
| | | |
Collapse
|
3
|
Gryl M, Kozieł M, Nowakowska K. The mystery of a co-crystal disappearing polymorph – case solved with quantum crystallography methods. Acta Cryst Sect A 2022. [DOI: 10.1107/s2053273322095171] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 03/19/2023]
|
4
|
Nowakowska K, Oszajca M, Nitek W, Gryl M, Kozieł M, Łasocha W. The synthesis and crystal structure of novel coordination polymers of cadmium(II) with hexamethylenetetramine ligand. Acta Cryst Sect A 2022. [DOI: 10.1107/s2053273322092713] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 03/19/2023]
|
5
|
Taavitsainen S, Engedal N, Cao S, Handle F, Erickson A, Prekovic S, Wetterskog D, Tolonen T, Vuorinen EM, Kiviaho A, Nätkin R, Häkkinen T, Devlies W, Henttinen S, Kaarijärvi R, Lahnalampi M, Kaljunen H, Nowakowska K, Syvälä H, Bläuer M, Cremaschi P, Claessens F, Visakorpi T, Tammela TL, Murtola T, Granberg KJ, Lamb AD, Ketola K, Mills IG, Attard G, Wang W, Nykter M, Urbanucci A. Abstract 401: Single-cell transcriptome and chromatin sequencing uncover gene expression and gene regulatory patterns associated with enzalutamide resistance. Cancer Res 2022. [DOI: 10.1158/1538-7445.am2022-401] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Resistance to androgen receptor-targeted therapy due to tumor heterogeneity and clonal evolution is a key challenge for improving prostate cancer outcomes. Despite this, the transcriptomic and chromatin accessibility changes contributing to the emergence of resistance remain incompletely understood at the level of individual cells. Using single-cell assays for transposase-accessible chromatin (ATAC) and RNA sequencing in models of early treatment response and resistance to enzalutamide, we previously identified pre-existing and persistent cell subpopulations that possess regenerative potential when subjected to treatment. Here we analyze the chromatin and transcriptomes of these single cells to characterize their gene regulation and gene expression trajectories. We present evidence of a model of enzalutamide resistance emergence in which the pre-existing and treatment-persistent cells regenerate the bulk of resistant cells. This process is underpinned by chromatin reprogramming that increases the overall relaxation of chromatin upon resistance. We show that the reprogramming of the chromatin further differentially contributes to transcription factor-mediated transcriptional reprogramming via DNA motif exposure in different cell subpopulations. For example, in the treatment-persistent cells, we identify chromatin configurations characterized by the exposure of DNA motifs for GATA2, RELA (a NFkB subunit), CREB1, and E2F1. Pre-existing and treatment-persistent cells consistently display transcriptional features of high developmental potential and RNA velocity analysis identifies them as precursors of cell populations that arise from enzalutamide treatment. We also analyze the pre-existing and treatment-persistent cells in spatial transcriptomics of prostate cancer patient specimens based on their characteristic gene expression profiles. We find these cells to be enriched in cancerous regions of the tissue but also detect them within apparent benign regions, which has potential implications for treatment choice. In summary, we show patterns of gene expression regulation in preclinical models and patient samples that uncover mechanisms of resistance to androgen receptor-targeted therapy in prostate cancer.
Citation Format: Sinja Taavitsainen, Nikolai Engedal, Shaolong Cao, Florian Handle, Andrew Erickson, Stefan Prekovic, Daniel Wetterskog, Teemu Tolonen, Elisa M. Vuorinen, Antti Kiviaho, Reetta Nätkin, Tomi Häkkinen, Wout Devlies, Sallamari Henttinen, Roosa Kaarijärvi, Mari Lahnalampi, Heidi Kaljunen, Karolina Nowakowska, Heimo Syvälä, Merja Bläuer, Paolo Cremaschi, Frank Claessens, Tapio Visakorpi, Teuvo L. Tammela, Teemu Murtola, Kirsi J. Granberg, Alastair D. Lamb, Kirsi Ketola, Ian G. Mills, Gerhardt Attard, Wenyi Wang, Matti Nykter, Alfonso Urbanucci. Single-cell transcriptome and chromatin sequencing uncover gene expression and gene regulatory patterns associated with enzalutamide resistance [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 401.
Collapse
Affiliation(s)
| | - Nikolai Engedal
- 2Institute for Cancer Research, Oslo University Hospital, Oslo, Norway
| | - Shaolong Cao
- 3The University of Texas MD Anderson Cancer Center, Houston, TX
| | | | | | - Stefan Prekovic
- 6Oncode Institute, The Netherlands Cancer Institute, Amsterdam, Netherlands
| | | | - Teemu Tolonen
- 8Fimlab Laboratories, Tampere University Hospital, Tampere, Finland
| | | | - Antti Kiviaho
- 1Tampere University and Tays Cancer Center, Tampere, Finland
| | - Reetta Nätkin
- 1Tampere University and Tays Cancer Center, Tampere, Finland
| | - Tomi Häkkinen
- 1Tampere University and Tays Cancer Center, Tampere, Finland
| | | | | | | | | | | | | | - Heimo Syvälä
- 1Tampere University and Tays Cancer Center, Tampere, Finland
| | - Merja Bläuer
- 1Tampere University and Tays Cancer Center, Tampere, Finland
| | - Paolo Cremaschi
- 7University College London Cancer Institute, London, United Kingdom
| | | | - Tapio Visakorpi
- 1Tampere University and Tays Cancer Center, Tampere, Finland
| | | | - Teemu Murtola
- 1Tampere University and Tays Cancer Center, Tampere, Finland
| | | | | | - Kirsi Ketola
- 10University of Eastern Finland, Kuopio, Finland
| | | | - Gerhardt Attard
- 7University College London Cancer Institute, London, United Kingdom
| | - Wenyi Wang
- 3The University of Texas MD Anderson Cancer Center, Houston, TX
| | - Matti Nykter
- 1Tampere University and Tays Cancer Center, Tampere, Finland
| | - Alfonso Urbanucci
- 2Institute for Cancer Research, Oslo University Hospital, Oslo, Norway
| |
Collapse
|
6
|
Taavitsainen S, Engedal N, Cao S, Handle F, Erickson A, Prekovic S, Wetterskog D, Tolonen T, Vuorinen EM, Kiviaho A, Nätkin R, Häkkinen T, Devlies W, Henttinen S, Kaarijärvi R, Lahnalampi M, Kaljunen H, Nowakowska K, Syvälä H, Bläuer M, Cremaschi P, Claessens F, Visakorpi T, Tammela TLJ, Murtola T, Granberg KJ, Lamb AD, Ketola K, Mills IG, Attard G, Wang W, Nykter M, Urbanucci A. Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse. Nat Commun 2021; 12:5307. [PMID: 34489465 PMCID: PMC8421417 DOI: 10.1038/s41467-021-25624-1] [Citation(s) in RCA: 46] [Impact Index Per Article: 15.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2021] [Accepted: 08/23/2021] [Indexed: 02/08/2023] Open
Abstract
Prostate cancer is heterogeneous and patients would benefit from methods that stratify those who are likely to respond to systemic therapy. Here, we employ single-cell assays for transposase-accessible chromatin (ATAC) and RNA sequencing in models of early treatment response and resistance to enzalutamide. In doing so, we identify pre-existing and treatment-persistent cell subpopulations that possess regenerative potential when subjected to treatment. We find distinct chromatin landscapes associated with enzalutamide treatment and resistance that are linked to alternative transcriptional programs. Transcriptional profiles characteristic of persistent cells are able to stratify the treatment response of patients. Ultimately, we show that defining changes in chromatin and gene expression in single-cell populations from pre-clinical models can reveal as yet unrecognized molecular predictors of treatment response. This suggests that the application of single-cell methods with high analytical resolution in pre-clinical models may powerfully inform clinical decision-making.
Collapse
Affiliation(s)
- S Taavitsainen
- Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center, Tampere, Finland
| | - N Engedal
- Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway
| | - S Cao
- Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - F Handle
- Molecular Endocrinology Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium
- Department of Urology, Division of Experimental Urology, Medical University of Innsbruck, Innsbruck, Austria
| | - A Erickson
- Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK
| | - S Prekovic
- Division of Oncogenomics, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands
| | - D Wetterskog
- University College London Cancer Institute, London, UK
| | - T Tolonen
- Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center, Tampere, Finland
- Department of Pathology, Fimlab Laboratories, Tampere University Hospital, Tampere, Finland
| | - E M Vuorinen
- Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center, Tampere, Finland
| | - A Kiviaho
- Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center, Tampere, Finland
| | - R Nätkin
- Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center, Tampere, Finland
| | - T Häkkinen
- Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center, Tampere, Finland
| | - W Devlies
- Molecular Endocrinology Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium
- Department of Urology, UZ Leuven, Leuven, Belgium
| | - S Henttinen
- Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center, Tampere, Finland
| | - R Kaarijärvi
- Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland
| | - M Lahnalampi
- Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland
| | - H Kaljunen
- Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland
| | - K Nowakowska
- University College London Cancer Institute, London, UK
| | - H Syvälä
- Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center, Tampere, Finland
| | - M Bläuer
- Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center, Tampere, Finland
| | - P Cremaschi
- University College London Cancer Institute, London, UK
| | - F Claessens
- Molecular Endocrinology Laboratory, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium
| | - T Visakorpi
- Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center, Tampere, Finland
- Fimlab Laboratories, Ltd, Tampere University Hospital, Tampere, Finland
| | - T L J Tammela
- Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center, Tampere, Finland
| | - T Murtola
- Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center, Tampere, Finland
| | - K J Granberg
- Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center, Tampere, Finland
| | - A D Lamb
- Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK
- Department of Urology, Churchill Hospital Cancer Centre, Oxford, UK
| | - K Ketola
- Institute of Biomedicine, University of Eastern Finland, Kuopio, Finland
| | - I G Mills
- Nuffield Department of Surgical Sciences, University of Oxford, Oxford, UK
- Patrick G Johnston Centre for Cancer Research, Queen's University of Belfast, Belfast, UK
- Centre for Cancer Biomarkers (CCBIO), University of Bergen, Bergen, Norway
| | - G Attard
- University College London Cancer Institute, London, UK
| | - W Wang
- Department of Bioinformatics and Computational Biology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
| | - M Nykter
- Prostate Cancer Research Center, Faculty of Medicine and Health Technology, Tampere University and Tays Cancer Center, Tampere, Finland.
| | - A Urbanucci
- Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway.
| |
Collapse
|
7
|
Nowakowska K, Królewicz E, Gamian A, Barg W. Basophil activation test in allergy diagnostics. POSTEP HIG MED DOSW 2020. [DOI: 10.5604/01.3001.0014.5766] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
The prevalence of allergic diseases in Poland and in the world continues to rise in recent
years. The most commonly used methods for diagnosing IgE – dependent allergies are skin
prick testing (SPT) and assessment of specific IgE (sIgE) directed against specific allergens.
However, both methods have some disadvantages and the obtained results may be inconsistent.
In particular, routine diagnostic tests are not always effective for some drugs and foods.
Consequently, additional laboratory tools should be used. Basophil activation test (BAT)
based on flow cytometry is a promising diagnostic method. The present paper demonstrates
the usefulness and effectiveness of BAT protocols in allergy diagnosis in scientific research.
In comparison to routinely used diagnostic methods, BAT is an expensive and complicated
laboratory tool. However, it offers the possibility to efficiently and effectively recognize
allergies. Introducing BAT into routine diagnostics in allergology is problematic because this
method has not yet been standardized and validated. Therefore, there is a justified need to
continue research in this field. If standardized and validated, BAT may offer a reasonable
improvement in allergy diagnostics in the future.
Collapse
Affiliation(s)
- Karolina Nowakowska
- Katedra i Klinika Chorób Wewnętrznych, Pneumonologii i Alergologii, Uniwersytet Medyczny im. Piastów Śląskich we Wrocławiu
| | - Emilia Królewicz
- Katedra i Zakład Biochemii Lekarskiej, Uniwersytet Medyczny im. Piastów Śląskich we Wrocławiu
| | - Andrzej Gamian
- Katedra i Zakład Biochemii Lekarskiej, Uniwersytet Medyczny im. Piastów Śląskich we Wrocławiu
| | - Wojciech Barg
- Katedra i Klinika Chorób Wewnętrznych, Pneumonologii i Alergologii, Uniwersytet Medyczny im. Piastów Śląskich we Wrocławiu
| |
Collapse
|
8
|
Nowakowska K, Giebułtowicz J, Kamaszewski M, Adamski A, Szudrowicz H, Ostaszewska T, Solarska-Dzięciołowska U, Nałęcz-Jawecki G, Wroczyński P, Drobniewska A. Acute exposure of zebrafish (Danio rerio) larvae to environmental concentrations of selected antidepressants: Bioaccumulation, physiological and histological changes. Comp Biochem Physiol C Toxicol Pharmacol 2020; 229:108670. [PMID: 31733407 DOI: 10.1016/j.cbpc.2019.108670] [Citation(s) in RCA: 22] [Impact Index Per Article: 5.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/06/2019] [Revised: 10/09/2019] [Accepted: 11/12/2019] [Indexed: 12/13/2022]
Abstract
Antidepressants have been detected in surface waters worldwide at ng-μg/L concentration. These compounds can exert adverse effects on fish even at low levels. But, all previous analyses have concentrated on adult fish. The aim of the study was to assess the effect of environmental concentrations of sertraline, paroxetine, fluoxetine and mianserin, and their mixtures on such unusual endpoints as physiological and histological changes of zebrafish (Danio rerio) larvae. We also determined the bioconcentration of the pharmaceuticals. Fish Embryo Toxicity test was used to analyze the influence on developmental progression. Histological sections were stained with hematoxylin and eosin. Proliferating cells in liver were determined immunohistochemically by detection of Proliferating Cell Nuclear Antigens. The bioconcentration factor was measured by liquid chromatography coupled to mass spectrometry. Pharmaceuticals were used at low, medium and high concentrations in mixtures and at medium concentration as single compound. Exposure to the analyzed pharmaceuticals increased the rate of abnormal embryo and larvae development, accelerated the hatching time and affected the total hatching rate. Three-times lower proliferation of hepatocytes was observed in larvae exposed to paroxetine, mianserin, sertraline and the mixture of the pharmaceuticals at the highest concentrations. The highest bioaccumulation factor (BCF) was obtained for sertraline. The BCF of the analyzed compounds was higher if the organisms were exposed to the mixtures than to single pharmaceuticals. To conclude, the exposure of zebrafish larvae to selected antidepressants and their mixtures may cause disturbances in the organogenesis of fish even at environmental concentrations.
Collapse
Affiliation(s)
- Karolina Nowakowska
- Department of Bioanalysis and Drugs Analysis, Faculty of Pharmacy, Medical University of Warsaw, 1 Banacha Street, Warsaw PL-02097, Poland; Department of Environmental Health Sciences, Faculty of Pharmacy, Medical University of Warsaw, 1 Banacha Street, Warsaw PL-02097, Poland
| | - Joanna Giebułtowicz
- Department of Bioanalysis and Drugs Analysis, Faculty of Pharmacy, Medical University of Warsaw, 1 Banacha Street, Warsaw PL-02097, Poland.
| | - Maciej Kamaszewski
- Department of Ichthyology and Biotechnology in Aquaculture, Warsaw University of Life Sciences-SGGW, 8 Ciszewskiego Street, Warsaw PL-02-786, Poland
| | - Antoni Adamski
- Department of Ichthyology and Biotechnology in Aquaculture, Warsaw University of Life Sciences-SGGW, 8 Ciszewskiego Street, Warsaw PL-02-786, Poland; Institute of Biochemistry and Biophysics, Polish Academy of Science, 5a Pawinskiego Street, Warsaw PL-02106, Poland
| | - Hubert Szudrowicz
- Department of Ichthyology and Biotechnology in Aquaculture, Warsaw University of Life Sciences-SGGW, 8 Ciszewskiego Street, Warsaw PL-02-786, Poland
| | - Teresa Ostaszewska
- Department of Ichthyology and Biotechnology in Aquaculture, Warsaw University of Life Sciences-SGGW, 8 Ciszewskiego Street, Warsaw PL-02-786, Poland
| | - Urszula Solarska-Dzięciołowska
- Department of Bioanalysis and Drugs Analysis, Faculty of Pharmacy, Medical University of Warsaw, 1 Banacha Street, Warsaw PL-02097, Poland
| | - Grzegorz Nałęcz-Jawecki
- Department of Environmental Health Sciences, Faculty of Pharmacy, Medical University of Warsaw, 1 Banacha Street, Warsaw PL-02097, Poland
| | - Piotr Wroczyński
- Department of Bioanalysis and Drugs Analysis, Faculty of Pharmacy, Medical University of Warsaw, 1 Banacha Street, Warsaw PL-02097, Poland
| | - Agata Drobniewska
- Department of Environmental Health Sciences, Faculty of Pharmacy, Medical University of Warsaw, 1 Banacha Street, Warsaw PL-02097, Poland
| |
Collapse
|
9
|
Nowakowska K, Pacholczak A, Tepper W. The effect of selected growth regulators and culture media on regeneration of Daphne mezereum L. ‘Alba’. Rend Fis Acc Lincei 2019. [DOI: 10.1007/s12210-019-00777-w] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
10
|
Jayaram A, Nowakowska K, Mateo J, Hernandez T, Kumar S, Fulton B, Nava Rodrigues D, Riisnaes R, Zukiwski A, Proniuk S, Bexon A, Bisaha J, Bianchini D, Zafeiriou Z, Lopez R, Tunariu N, Pacey S, Jones R, de Bono JS, Attard G. Phase 1-2 study of progesterone receptor (PR) inhibition with extended-release (ER) onapristone (ONA) alone or in combination with abiraterone (AA) in patients (pts) with castration-resistant prostate cancer (CRPC) incorporating plasma DNA analysis to define androgen receptor (AR) status. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx513.007] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
11
|
Jayaram A, Nowakowska K, Mateo J, Kumar S, Hernandez T, Fulton B, Nava Rodrigues D, Riisnaes R, Zukiwski A, Bexon AS, Proniuk S, Barranco C, Bianchini D, Zafeirou Z, Perez Lopez R, Tunariu N, Pacey S, Jones RJ, De Bono JS, Attard G. Phase 1-2 study of progesterone receptor (PR) inhibition with extended-release (ER) onapristone (ONA) alone or in combination with abiraterone (AA) in patients (pts) with castration-resistant prostate cancer (CRPC) incorporating plasma DNA analysis to define androgen receptor (AR) status. J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.15_suppl.5071] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5071 Background: An urgent need exists for new therapies after progression (PD) onAA and enzalutamide (ENZ). Increased PR expression or progesterone-activating AR mutations have been associated with resistance to AR targeting. We aimed to test ONA, a type I PR antagonist with clinical activity in PRpos cancers, in AA/enz-resistant CRPC. In a prospectively defined exploratory analysis, we aimed to report outcome by plasma AR status ( pAR). Methods: This was a multi-institution, open label phase I/II clinical trial in pts progressing after ENZ/AA. Pts were first treated with single agent (SA) ONA using a randomised dose escalation design. ONA at 2 doses was then combined with AA (1000mg od with pred 5mg bid) in pts progressing on AA. The primary end-points were safety, pharmacokinetics (PK) and anti-tumor activity split by p AR. Archival and metastatic biopsies were collected when possible and tested for PR status. p AR was studied using previous methods (Romanel STM 2015). Results: 21 pts received SA ONA (5 = 10mg/ 5 = 20mg/ 4 = 30mg/ 4 = 40mg /3 = 50mg BID) and 15 pts received ONA-AA combination (5 = 30mg ONA BID, 10 = 50mg ONA BID). There were not DLTs or significant LFT abnormalities and no G3/4 adverse events (AE), no treatment discontinuations due to AEs and no SAEs considered related to ONA. PK in SA ONA observed active plasma concentrations and no interaction with AA. Of 32 evaluated pts 15 had a 2105T > A (p.L702H) or 2632A > G (p.T878A) AR mutation detected in plasma pre-treatment and 1 had AR copy number gain. PSA declines were not observed with SA ONA but in 2 pts with combination (-30%, -7%) who were AR normal. The rPFS on SA ONA was 2.8 months for AR normal and 2.6 for AR aberrant (Hazard ratio (HR) 1.41; 95% CI, 0.62-3.72; P 0.48) and on combination was 4.4 months for AR normal (8/15) and 2.2 for AR aberrant (7/15) (HR 6.08; 95%CI, 6.32-221.9; P < 0.001). Conclusions: ONA is safe in CRPC as SA and in combination with AA. There was no difference in rPFS by p AR status for SA ONA but on the combination with AA, pts who were plasma AR normal had a significantly longer rPFS. Clinical trial information: NCT02049190.
Collapse
Affiliation(s)
- Anuradha Jayaram
- Institute of Cancer Research and The Royal Marsden NHS Trust Foundation, Sutton, United Kingdom
| | - Karolina Nowakowska
- The Institue of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom
| | - Joaquin Mateo
- The Institute of Cancer Research and The Royal Marsden Hospital, London, United Kingdom
| | - Sanjeev Kumar
- Cambridge University Hospitals, Cambridge, United Kingdom
| | | | - Ben Fulton
- Institute of Cancer Sciences, Glasgow, United Kingdom
| | - Daniel Nava Rodrigues
- The Institue of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom
| | - Ruth Riisnaes
- Cancer Biomarkers Laboratory, The Institute of Cancer Research, London, United Kingdom
| | | | | | | | | | - Diletta Bianchini
- The Institue of Cancer Research, The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - Zafeiris Zafeirou
- The Institue of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom
| | - Raquel Perez Lopez
- The Institute of Cancer Research and The Royal Marsden Hospital, London, United Kingdom
| | - Nina Tunariu
- The Institute of Cancer Research and The Royal Marsden Hospital, London, United Kingdom
| | - Simon Pacey
- The University of Cambridge, Addenbrookes Hospital, Cambridge, United Kingdom
| | - Robert J. Jones
- University of Glasgow, Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
| | - Johann S. De Bono
- The Institute of Cancer Research and The Royal Marsden Hospital, London, United Kingdom
| | - Gerhardt Attard
- The Institute of Cancer Research and The Royal Marsden Hospital, Sutton, United Kingdom
| |
Collapse
|
12
|
Jayaram A, Nowakowska K, Mateo J, Nava Rodrigues D, Riisnaes R, Zukiwski A, Proniuk S, Bexon AS, Bisaha J, Bianchini D, Zafeiriou Z, Perez Lopez R, Tunariu N, De Bono JS, Attard G. Phase 1-2 study of progesterone receptor (PR) inhibition with extended-release (ER) onapristone (ONA) in patients (pts) with castration-resistant prostate cancer (CRPC): PK, safety and PR testing results from the dose escalation cohort. J Clin Oncol 2015. [DOI: 10.1200/jco.2015.33.15_suppl.5051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- Anuradha Jayaram
- The Institute of Cancer Research & The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom
| | - Karolina Nowakowska
- The Institute of Cancer Research & The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom
| | | | - Daniel Nava Rodrigues
- The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom
| | - Ruth Riisnaes
- The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom
| | | | | | | | | | - Diletta Bianchini
- The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - Zafeiris Zafeiriou
- The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom
| | | | - Nina Tunariu
- The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, London, United Kingdom
| | - Johann Sebastian De Bono
- The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom
| | - Gerhardt Attard
- The Institute of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom
| |
Collapse
|
13
|
Crespo M, van Dalum G, Ferraldeschi R, Zafeiriou Z, Sideris S, Lorente D, Bianchini D, Rodrigues DN, Riisnaes R, Miranda S, Figueiredo I, Flohr P, Nowakowska K, de Bono JS, Terstappen LWMM, Attard G. Androgen receptor expression in circulating tumour cells from castration-resistant prostate cancer patients treated with novel endocrine agents. Br J Cancer 2015; 112:1166-74. [PMID: 25719830 PMCID: PMC4385957 DOI: 10.1038/bjc.2015.63] [Citation(s) in RCA: 54] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2014] [Revised: 01/19/2015] [Accepted: 01/27/2015] [Indexed: 01/15/2023] Open
Abstract
BACKGROUND Abiraterone and enzalutamide are novel endocrine treatments that abrogate androgen receptor (AR) signalling in castration-resistant prostate cancer (CRPC). Here, we developed a circulating tumour cells (CTCs)-based assay to evaluate AR expression in real-time in CRPC and investigated nuclear AR expression in CTCs in patients treated with enzalutamide and abiraterone. METHODS CTCs were captured and characterised using the CellSearch system. An automated algorithm to identify CTCs and quantify AR expression was employed. The primary aim was to evaluate the association between CTC AR expression and prior treatment with abiraterone or enzalutamide. RESULTS AR expression in CTCs was evaluated in 94 samples from 48 metastatic CRPC patients. We observed large intra-patient heterogeneity of AR expression in CTCs. Prior exposure to abiraterone or enzalutamide was not associated with a change in CTCs AR expression (median intensity and distribution of AR-positive classes). In support of this, we also confirmed maintained nuclear AR expression in tissue samples collected after progression on abiraterone. AR staining also identified additional AR-positive CD45-negative circulating cells that were CK-negative/weak and therefore missed using standard protocols. The number of these events correlated with traditional CTCs and was associated with worse outcome on univariate analysis. CONCLUSIONS We developed a non-invasive method to monitor AR nuclear expression in CTCs. Our studies confirm nuclear AR expression in CRPC patients progressing on novel endocrine treatments. Owing to the significant heterogeneity of AR expression in CTCs, studies in larger cohorts of patients are required to identify associations with outcome.
Collapse
Affiliation(s)
- M Crespo
- Section of Medicine, The Institute of Cancer Research, Sutton, Surrey, SM2 5NG, UK
| | - G van Dalum
- Department of Medical Cell BioPhysics, MIRA Institute, University of Twente, 7522ND, Enschede, The Netherlands
| | - R Ferraldeschi
- Section of Medicine, The Institute of Cancer Research, Sutton, Surrey, SM2 5NG, UK
- Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, SM2 5NG, UK
| | - Z Zafeiriou
- Section of Medicine, The Institute of Cancer Research, Sutton, Surrey, SM2 5NG, UK
- Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, SM2 5NG, UK
| | - S Sideris
- Section of Medicine, The Institute of Cancer Research, Sutton, Surrey, SM2 5NG, UK
- Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, SM2 5NG, UK
| | - D Lorente
- Section of Medicine, The Institute of Cancer Research, Sutton, Surrey, SM2 5NG, UK
- Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, SM2 5NG, UK
| | - D Bianchini
- Section of Medicine, The Institute of Cancer Research, Sutton, Surrey, SM2 5NG, UK
- Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, SM2 5NG, UK
| | - D N Rodrigues
- Section of Medicine, The Institute of Cancer Research, Sutton, Surrey, SM2 5NG, UK
| | - R Riisnaes
- Section of Medicine, The Institute of Cancer Research, Sutton, Surrey, SM2 5NG, UK
| | - S Miranda
- Section of Medicine, The Institute of Cancer Research, Sutton, Surrey, SM2 5NG, UK
| | - I Figueiredo
- Section of Medicine, The Institute of Cancer Research, Sutton, Surrey, SM2 5NG, UK
| | - P Flohr
- Section of Medicine, The Institute of Cancer Research, Sutton, Surrey, SM2 5NG, UK
| | - K Nowakowska
- Section of Medicine, The Institute of Cancer Research, Sutton, Surrey, SM2 5NG, UK
| | - J S de Bono
- Section of Medicine, The Institute of Cancer Research, Sutton, Surrey, SM2 5NG, UK
- Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, SM2 5NG, UK
| | - L W M M Terstappen
- Department of Medical Cell BioPhysics, MIRA Institute, University of Twente, 7522ND, Enschede, The Netherlands
| | - G Attard
- Section of Medicine, The Institute of Cancer Research, Sutton, Surrey, SM2 5NG, UK
- Prostate Cancer Targeted Therapy Group and Drug Development Unit, The Royal Marsden NHS Foundation Trust, Sutton, Surrey, SM2 5NG, UK
| |
Collapse
|
14
|
Richards J, Lim AC, Hay CW, Taylor AE, Wingate A, Nowakowska K, Pezaro C, Carreira S, Goodall J, Arlt W, McEwan IJ, de Bono JS, Attard G. Interactions of abiraterone, eplerenone, and prednisolone with wild-type and mutant androgen receptor: a rationale for increasing abiraterone exposure or combining with MDV3100. Cancer Res 2012; 72:2176-82. [PMID: 22411952 DOI: 10.1158/0008-5472.can-11-3980] [Citation(s) in RCA: 213] [Impact Index Per Article: 17.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Prostate cancer progression can be associated with androgen receptor (AR) mutations acquired following treatment with castration and/or an antiandrogen. Abiraterone, a rationally designed inhibitor of CYP17A1 recently approved for the treatment of docetaxel-treated castration-resistant prostate cancer (CRPC), is often effective, but requires coadministration with glucocorticoids to curtail side effects. Here, we hypothesized that progressive disease on abiraterone may occur secondary to glucocorticoid-induced activation of mutated AR. We found that prednisolone plasma levels in patients with CRPC were sufficiently high to activate mutant AR. Mineralocorticoid receptor antagonists, such as spironolactone and eplerenone that are used to treat side effects related to mineralocorticoid excess, can also bind to and activate signaling through wild-type or mutant AR. Abiraterone inhibited in vitro proliferation and AR-regulated gene expression of AR-positive prostate cancer cells, which could be explained by AR antagonism in addition to inhibition of steroidogenesis. In fact, activation of mutant AR by eplerenone was inhibited by MDV3100, bicalutamide, or greater concentrations of abiraterone. Therefore, an increase in abiraterone exposure could reverse resistance secondary to activation of AR by residual ligands or coadministered drugs. Together, our findings provide a strong rationale for clinical evaluation of combined CYP17A1 inhibition and AR antagonism.
Collapse
Affiliation(s)
- Juliet Richards
- Section of Medicine, The Institute of Cancer Research, Sutton, Surrey, United Kingdom
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Wegrzynowska-Teodorczyk K, Rudzinska E, Nowakowska K, Lazorczyk M, Lejczak A, Jankowska E, Banasiak W, Ponikowski P, Wozniewski M. 40 LOW LEVEL OF PHYSICAL FITNESS IS A PREDICTOR OF POOR PROGNOSIS IN MEN WITH STABLE HEART FAILURE. Maturitas 2012. [DOI: 10.1016/s0378-5122(12)70151-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
|
16
|
Nowakowska K, Jabłkowska K, Borkowska A. Verbal working memory and executive dysfunctions in patients with alcohol addiction. Eur Psychiatry 2007. [DOI: 10.1016/j.eurpsy.2007.01.645] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
|
17
|
Gołabek B, Słowik M, Grabowska M, Kowalska B, Nowakowska K, Nowaczewska I. [Evaluation of treatment and preventive care for recurrent urolithiasis in children]. Med Wieku Rozwoj 1999; 3:259-80. [PMID: 10910656] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/17/2023]
Abstract
Among 425 children with urolithiasis treated in the Paediatric Clinical Department of the National Research Institute of Mother and Child in Warsaw between 1976-1997, 50 of them i.e. 11.7% (26 boys and 24 girls) had recurrent urolithiasis. Patients' age was from 10 months to 16 years and 5 months. The number of recurrences of uroliothiasis before treatment in the Institute was from 1 to 8. Most of the children had numerous surgical operations, some of them excreted stones spontaneously. The etiology was determined in all cases. A metabolic cause of urolithiasis was found in 34 cases, i.e. 68% of the analysed group. They were as follows: idiopathic hypercalcuria--24 cases, uric acid urolithiasis--5 cases, cystynuria--4 cases, and incomplete distal renal tubular acidosis--1 case. Other reasons for urolithiasis were: infection--7 cases, idiopathic urolithiasis--8 cases, ren spongiosum--1 case. Prevention of recurrences depending on the etiology was successful. In 45 cases no recurrences were found. Recurrent urolithiasis was observed in 4 cases of cystynuria and in one case of incomplete tubular acidosis. The observation period was from 3-19 years.
Collapse
Affiliation(s)
- B Gołabek
- Klinika Pediatrii IMD, Instytut Matki i Dziecka w Warszawie
| | | | | | | | | | | |
Collapse
|
18
|
Gołabek B, Nowakowska K, Słowik M, Paruszkiewicz G. [Clinical evaluation of Uro-Vaxom in treatment of recurrent urinary tract infections in girls]. Pediatr Pol 1995; 70:1053-7. [PMID: 8649945] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/01/2023]
Abstract
Uro-Vaxom was used in the treatment of recurrent urinary tract infections in 28 girls. Most of them (27/28) tolerated the drug very well, no side effects were observed. We stopped administration of the Uro-Vaxom in one girl during the first month of treatment because of vomiting. Uro-Vaxom efficiency was, therefore, evaluated in 27 girls. Uro-Vaxom was found to be a valuable drug, supplementing antibiotic therapy in recurrent urinary tract infections caused by E. coli.
Collapse
Affiliation(s)
- B Gołabek
- Klinika Pediatrii Instytutu Matki i Dziecka w Warszawie
| | | | | | | |
Collapse
|
19
|
Pawluch D, Szozda G, Nowakowska K, Drejewicz H. [Bacterial flora in urinary tract infections of children and susceptibility to drugs]. Med Dosw Mikrobiol 1994; 46:67-71. [PMID: 7967933] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 05/22/2023]
Abstract
The material consisted of 902 strains isolated from children with urinary tract infection with significant bacteriuria. Among isolated strains, Enterobacteriaceae consisted 67.4%, Gram-positive cocci 18.8% and non-fermenting Gram-negative bacilli (both against Gram-negative bacilli and Gram-positive cocci), appeared aminoglycosides and III generation cephalosporins (from 63 to 83% of susceptible strains). K. pneumoniae and P. aeruginosa were most resistant to antimicrobials tested. The authors point out that empiric antibiotic therapy of bacterial urinary tract infections in children which is not preceded by identification of the pathogen and determination of its drug susceptibility, can be ineffective in over 50% of cases.
Collapse
Affiliation(s)
- D Pawluch
- Zakład Immunologii Instytutu Matki i Dziecka w Warszawie
| | | | | | | |
Collapse
|
20
|
Gołeebiowska H, Prokopczyk J, Pawluch D, Nowakowska K, Bozkowa K. The usefulness of erythromycin in paediatrics. J Chemother 1989; 1:689-90. [PMID: 16312594] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 05/05/2023]
Affiliation(s)
- H Gołeebiowska
- National Research Institute of Mother and Child. Kasprzaka 17a street, 01-211 Warsaw, Poland
| | | | | | | | | |
Collapse
|
21
|
Szozda G, Nowakowska K. Frequency of enteropathogenic serotypes of Escherichia coli in infantile diarrhoea in the years 1975-1983 and characteristics of their drug-sensitivity. Mater Med Pol 1988; 20:28-30. [PMID: 3065579] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
|
22
|
Nowakowska K, Szozda G, Pawluch D. [Sensitivity of bacterial flora of the gastrointestinal tract to nifuroxazide]. Pol Tyg Lek 1987; 42:957-8. [PMID: 3684774] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
|
23
|
Szozda G, Nowakowska K, Pawluch D. [Comparative evaluation of the antibacterial activity of nitrofuran derivatives]. Pol Tyg Lek 1987; 42:967-9. [PMID: 3120163] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
|
24
|
Pawluch D, Nowakowska K, Szozda G. [Evaluation of the sensitivity of selected bacterial strains to cefuroxime]. Pol Tyg Lek 1986; 41:1184-5. [PMID: 3103111] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
|
25
|
Siwińska-Gołebiowska H, Szozda G, Nowakowska K, Konaszyc-Nagat J. [Use of cefadroxil in respiratory tract infections in children]. Pediatr Pol 1986; 61:172-6. [PMID: 3540830] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
|
26
|
Szozda G, Nowakowska K, Siwińska-Gołebiowska H. [Analysis of drug sensitivity of microorganisms isolated from children treated at the Institute of Mother and Child]. Pediatr Pol 1986; 61:32-40. [PMID: 3088539] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/04/2023]
|
27
|
|
28
|
Siwińska-Gołebiowska H, Borysewicz G, Smogorzewska E, Nowakowska K, Mańkowski T, Lewandowska J. [Immunological status of children with atopic hypersensitivity]. Pediatr Pol 1984; 59:949-54. [PMID: 6336049] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
|
29
|
Siwińska-Gołebiowska H, Kunicka A, Borysewicz G, Nowakowska K, Smogorzewska E, Duroś H, Perek D, Bozek J. [Studies on selected parameters of immunological reactivity in children with neuroblastoma]. Pediatr Pol 1981; 56:889-96. [PMID: 6975463] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 01/22/2023]
|
30
|
Janicki J, Sobkowska E, Warchalewski J, Nowakowska K, Chelkowski J, Stasińska B. Amino acid composition of cereal and oilseed. Nahrung 1973; 17:359-65. [PMID: 4737648 DOI: 10.1002/food.19730170311] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/12/2023]
Abstract
AbstractQuantitative amino acid composition of acid hydrolysates was determined for samples of some Polish varieties of cereal grain (wheat, rye, barley, oats, millet and buckwheat) and oilseed (rapeseed, sunflower, poppy and soybean). Comparison of investigated genera was done.
Collapse
|